Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial

阿利罗库单抗 医学 他汀类 内科学 危险系数 PCSK9 急性冠脉综合征 不利影响 安慰剂 心肌梗塞 心脏病学 胆固醇 置信区间 脂蛋白 低密度脂蛋白受体 替代医学 载脂蛋白A1 病理
作者
Rafael Díaz,Qian H Li,Deepak L. Bhatt,Vera Bittner,Marie T. Baccara‐Dinet,Shaun G. Goodman,J. Wouter Jukema,Takeshi Kimura,Alexander Parkhomenko,Robert Pordy,Željko Reiner,Matthew W. Sherwood,Michael Szarek,Hung‐Fat Tse,Harvey D. White,Doron Zahger,Andreas M. Zeiher,Gregory G. Schwartz,Philippe Gabríel Steg
出处
期刊:European Journal of Preventive Cardiology [Oxford University Press]
卷期号:28 (1): 33-43 被引量:43
标识
DOI:10.1177/2047487320941987
摘要

Abstract Aims Statins are pivotal to the secondary prevention of major adverse cardiovascular events, but some patients are statin-intolerant. We examined the effects of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab on the risk of major adverse cardiovascular events according to the intensity of background statin treatment. Methods and results The ODYSSEY OUTCOMES trial compared alirocumab with placebo in 18,924 patients with acute coronary syndrome and dyslipidaemia despite intensive or maximum-tolerated statin treatment (including no statin if intolerance was documented). The primary outcome (major adverse cardiovascular events) comprised coronary heart disease death, non-fatal myocardial infarction, ischaemic stroke, or unstable angina. Median follow-up was 2.8 years. Baseline statin treatment was high-intensity (88.8%), low/moderate-intensity (8.7%) or none (2.4%). Median baseline low-density lipoprotein cholesterol was 86, 89 and 139 mg/dL (P < 0.001) in these statin treatment categories, respectively. Alirocumab produced similar relative reductions in low-density lipoprotein cholesterol from baseline across statin treatment subgroups, but the mean absolute reductions differed (52.9, 56.7 and 86.1 mg/dL, respectively; P < 0.001). With placebo, the incidence of major adverse cardiovascular events was highest in the no statin subgroup (10.8%, 10.7% and 26.0% respectively). Alirocumab reduced major adverse cardiovascular events in each statin subgroup (hazard ratio 0.88, 95% confidence interval (CI) 0.80–0.96; 0.68, 0.49–0.94; and 0.65, 0.44–0.97, respectively; Pinteraction = 0.14) with a gradient of absolute risk reduction: 1.25%, 95% CI 0.34–2.16; 3.16%, 0.38–5.94; 7.97%, 0.42–15.51; Pinteraction = 0.106). Conclusions PCSK9 inhibition with alirocumab reduces the relative risk of major adverse cardiovascular events after acute coronary syndrome irrespective of background statin treatment. However, patients on no statin are at high absolute risk for recurrent major adverse cardiovascular events; alirocumab substantially reduces that risk. PCSK9 inhibition may be an important therapeutic strategy for statin-intolerant patients with acute coronary syndrome.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
柠檬茶完成签到,获得积分10
刚刚
小羊发布了新的文献求助10
刚刚
ZQY发布了新的文献求助10
刚刚
七颗茶香豆的应助被强强采纳,获得10
刚刚
小二郎的应助被tracy采纳,获得10
1秒前
秋风的应助被小巧的大米采纳,获得10
1秒前
hanser完成签到,获得积分10
1秒前
1秒前
lzl发布了新的文献求助20
2秒前
2秒前
慕青的应助被小毛球采纳,获得10
3秒前
秋风的应助被番茄小喵采纳,获得10
4秒前
4秒前
4秒前
bai发布了新的文献求助10
4秒前
单薄谷秋发布了新的文献求助10
4秒前
科目三的应助被暴龙战士采纳,获得10
4秒前
王冠军完成签到,获得积分10
5秒前
彭于晏的应助被Oo3采纳,获得10
5秒前
7秒前
追尾的猫完成签到,获得积分10
7秒前
7秒前
小木没有烦恼完成签到 ,获得积分10
7秒前
8秒前
8秒前
墨白发布了新的文献求助10
9秒前
9秒前
科研通AI6.4的应助被瑶崽采纳,获得10
11秒前
11秒前
英姑的应助被单薄谷秋采纳,获得10
11秒前
王一硕发布了新的文献求助10
12秒前
七颗茶香豆的应助被一团毛线采纳,获得10
12秒前
12秒前
秋风的应助被淡淡的香芦采纳,获得50
13秒前
Maestro_S的应助被杨芷昀采纳,获得30
13秒前
doctor完成签到,获得积分10
13秒前
ll完成签到,获得积分10
13秒前
论文顺利发布了新的文献求助10
14秒前
慕青的应助被咻咻采纳,获得10
15秒前
fanxiaojia完成签到 ,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193514
求助须知:如何正确求助?哪些是违规求助? 9579686
关于积分的说明 21866883
捐赠科研通 7793152
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560725
邀请新用户注册赠送积分活动 2484176